Where Our Funds Go

A very important aspect of every 501(c)(3) nonprofit organization is its transparency into where its funds actually go. The short answer to that question is easy—our beneficiary organization, which in 2016 and 2017 is the Pancreatic Cancer Action Network, and in past years has been the Leukemia & Lymphoma Society and St. Baldrick’s Foundation.

It is always our goal to pass through as much of the funds donated to Tap Cancer Out as possible through to our beneficiary organization. However, there is an oft-unspoken reality that running a business, even a nonprofit, requires an investment in operating costs. Even for a small nonprofit like us, those costs include merchandise expenses, venue rental fees, mat purchase and storage, software subscriptions, paid media (like Facebook Ads), the hosting fees for this website, marketing, travel, meals when on the road, and much, much more. These operating costs aren’t solely covered by donations. In fact, we cover much of them with other revenue streams, namely merchandise sales and registration fees.

Our pass through rates can be derived by dividing our Donation to Beneficiary by Total Donations Received. All our financials, including the Form 990 (2012 onward), Statement of Financial Activities (2012 onward), and Annual Reports (published each July, starting with 2014) are publicly available and uploaded for your convenience on our Annual Reports Page.

Below are our pass-through rates, including the amount of donations we received and the amount we donated to our beneficiary, on a year-by-year basis.

This means that in 4 years we’ve required about $0.10 per dollar donated to operate Tap Cancer Out.

How Our Beneficiary Gifts are Creating Change:

Cancer affects us all in so many different ways, and there are so many different types that it can become overwhelming. So when we created Tap Cancer Out, we decided that instead of focusing on fighting one type of cancer, we would support a different beneficiary every two years.

2012 – 2013: Leukemia & Lymphoma Foundation ($85,000 donated)

Group60k

We were honored to work with the Leukemia & Lymphoma Society as our inaugural beneficiary organization. Our donations to both the Connecticut and Massachusetts LLS chapters benefited localized patient support and education. It was important to us to work with the local chapters since our 2012 and 2013 fundraising tournaments took place in Stratford, CT, and Danvers, MA.

“The generous donations given by all of the participants and supporters of Tap Cancer Out enable The Leukemia & Lymphoma Society to provide patients and their families with much needed support as well as funding life saving research,” said Brandy Sinisi, Campaign Manager for the Leukemia & Lymphoma Society Connecticut Chapter. “Thank you to the entire Tap Cancer Out team and their supporters for their hard work and determination to put an end not just to blood cancers, but to all cancers.”

2014 – 2015: St. Baldrick’s Foundation ($236,000 donated)


As a partner of St. Baldrick’s, we had the opportunity to jointly fund four pediatric cancer research grants. The researchers included Dr. Colleen Annesley of Johns Hopkins Hospital in Baltimore, MD, Dr. Jennifer Wu of Boston’s Children’s Hospital in Boston, MA, Dr. Juan Vasquez (as seen in the above video) of Yale University School of Medicine in New Haven, CT, and Dr. Sun Choo of UCSD in San Diego, CA. You can read more about Dr. Annesley and Dr. Wu’s research in our 2014 Annual Report and more about Dr. Choo and Dr. Vasquez’s research in our 2015 Annual Report. We even had the honor of welcoming Dr. Wu at our 2014 Massachusetts BJJ Open and Dr. Choo at our 2016 San Diego BJJ Open to speak to our competitors and volunteers about how their research is helping improve cancer survivorship.

2016 – 2017: Pancreatic Cancer Action Network ($210,000 donated in ’16, $300,000 pledged in ’17)

With our newest partnership, we donated more than $200,000 in 2016 and aim to raise another $300,000 over the next two years total to help the Pancreatic Cancer Action Network make significant strides in early detection, treatment, and improving clinical trial opportunities for patients. In 2017 we are specifically funding one of PanCan’s Translational Research Grants.